Delete

Dechra’s Vetoryl Receives FDA Approval

The U.S. FDA has approved Dechra Veterinary Products’ Vetoryl Capsules.

Suggested Veterinary Products

The U.S. Food and Drug Administration has approved Dechra Veterinary Products’ Vetoryl (trilostane) Capsules.

The product is intended for treating pituitary-dependent hyperadrenocorticism, which comprises the majority of cases of Cushing’s syndrome in dogs.

Vetoryl also has received the designation status as a Minor Use Drug for treatment of hyperadrenocorticism caused by adrenal tumors, the first drug to receive approval for this indication and the first drug to receive a Minor Use designation in dogs, according to the company.

Dechra is based in Overland Park, Kan.

<HOME>

Leave a Comment

Comments

Your email address will not be published. Required fields are marked *